[Procalcitonin in the intensive care unit : Differential diagnostic and differential therapeutic possibilities].

Med Klin Intensivmed Notfmed

Klinik für Pneumologie und konservative Intensivmedizin, Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger Str. 86, 93049, Regensburg, Deutschland.

Published: October 2021

Procalcitonin (PCT) is formed in IL6-mediated, IL8-mediated, and TNFα-mediated systemic inflammation conditions, in multiple organs and structures of the body. In patients with sepsis, significantly increased PCT levels are found. The PCT levels are highly correlated with the severity of the illness, and decreased PCT levels under therapy correlates with a better prognosis. In the differential diagnosis, measuring the PCT level helps differentiate between bacterial and viral infections. Noninfectious inflammatory reactions can, however, show moderately increased PCT levels. Cut-off values depend on renal and hepatic function. A therapeutic algorithm using PCT levels could be used for determining duration of a course of antibiotics, which can reduce antibiotic usage. In this paper, the differential diagnostic and differential therapeutic possibilities of PCT levels for critically ill patients are discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323366PMC
http://dx.doi.org/10.1007/s00063-020-00703-1DOI Listing

Publication Analysis

Top Keywords

pct levels
24
differential diagnostic
8
diagnostic differential
8
differential therapeutic
8
pct
8
increased pct
8
levels
6
differential
5
[procalcitonin intensive
4
intensive care
4

Similar Publications

Objective: To assess whether patient experience is better for patients followed in a primary care team (PCT) than for patients with traditional follow-up in usual care.

Design: A cross-sectional survey based on a self-administered questionnaire.

Setting: Pays de la Loire geographical area (located on the French west coast).

View Article and Find Full Text PDF

Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy.

Biomed Pharmacother

March 2025

Group of Pathophysiology and Therapies for Vision Disorders, Príncipe Felipe Research Center (CIPF), Eduardo Primo Yúfera 3, Valencia 46012, Spain; Joint Research Unit on Rare Diseases CIPF-Health Research Institute Hospital La Fe (IIS-La Fe), Valencia 46026, Spain; Biomedical Research Networking Center in Rare Diseases (CIBER-ER), Institute of Health Carlos III, Monforte de Lemos, 3-5. Pabellón 11, Madrid 28029, Spain; Catholic University of Valencia (UCV), Faculty of Health Sciences, Quevedo, 2, Valencia 46001, Spain. Electronic address:

Retinitis pigmentosa is a genetically heterogeneous retinal degeneration process. There is hardly any treatment available. It is associated with extensive chronic inflammation and the release of proinflammatory cytokines such as TNFα.

View Article and Find Full Text PDF

Background: Nicotinamide, a form of B3 vitamin, is an NAD precursor that reduces pTau levels via histone deacetylase inhibition in murine models of Alzheimer's disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of early AD. While nicotinamide demonstrated good safety and tolerability, it did not significantly lower CSF pTau, the primary biomarker endpoint of the study.

View Article and Find Full Text PDF

Aim: We aimed to evaluate the utility of procalcitonin (PCT) as a biomarker for clinical severity grading of intra-abdominal infections (IAI) in hospital-admitted patients presenting with acute abdomen.

Methods: In this retrospective study, median PCT values were compared with conventional inflammatory biomarkers, including leukocyte count (LC), neutrophil count (NC), and C-reactive protein (CRP), within the patient population.

Results: Among the 245 patients included in the study, 58 (23.

View Article and Find Full Text PDF

Background: We aimed to investigate the correlations of prealbumin (PA), procalcitonin (PCT) and brain natriuretic peptide (BNP) with acute respiratory infection (ARI) in children.

Methods: A total of 120 children with ARI admitted from June 2021 through June 2023 were selected (an infection group) and divided into a bacteria group (n = 50) and a virus group (n = 70) according to the results of bacterial culture and serum test. Another 90 healthy children who underwent physical examination in the same period were selected as a control group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!